<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23140210</article-id><article-id pub-id-type="pmc">3514236</article-id><article-id pub-id-type="publisher-id">1471-2334-12-292</article-id><article-id pub-id-type="doi">10.1186/1471-2334-12-292</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Adherence to recommendations by infectious disease consultants and its influence on outcomes of intravenous antibiotic-treated hospitalized patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Fari&#x000f1;as</surname><given-names>Mar&#x000ed;a-Carmen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farinasc@unican.es</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Saravia</surname><given-names>Gabriela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gsavaria@yahoo.es</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Calvo-Montes</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jcalvo@humv.es</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Benito</surname><given-names>Natividad</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>nbenito@santpau.cat</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Mart&#x000ed;nez-Garde</surname><given-names>Juan-Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>farmgj@humv.es</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Fari&#x000f1;as-Alvarez</surname><given-names>Concepci&#x000f3;n</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>mariaconcepcion.farinas@scsalud.es</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Aguilar</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>laguilar@med.ucm.es</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Ag&#x000fc;ero</surname><given-names>Ram&#x000f3;n</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>nmlabr@humv.es</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Amado</surname><given-names>Jos&#x000e9;-Antonio</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>jamado@humv.es</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I9">9</xref><email>lmartinez@humv.es</email></contrib><contrib contrib-type="author" id="A11"><name><surname>G&#x000f3;mez-Fleitas</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>manuel.gomezfleitas@humv.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Infectious Diseases Unit, Hospital Universitario Marques de Valdecilla, School of Medicine, University of Cantabria, Av. Valdecilla s/n, 39008 Santander, Spain</aff><aff id="I2"><label>2</label>Microbiology Department, Hospital Universitario Marques de Valdecilla, School of Medicine, University of Cantabria, Av. Valdecilla s/n, 39008, Santander, Spain</aff><aff id="I3"><label>3</label>Infectious Diseases Unit, Hospital Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain</aff><aff id="I4"><label>4</label>Pharmacy Department, Hospital Universitario Marques de Valdecilla, Av. Valdecilla s/n, 39008, Santander, Spain</aff><aff id="I5"><label>5</label>Preventive Medicine Department, Hospital Sierrallana, B&#x000aa; Ganzo s/n, 39300, Torrelavega, Cantabria, Spain</aff><aff id="I6"><label>6</label>Microbiology Department, School of Medicine Universidad Complutense, Avda. Complutense s/n, 28040, Madrid, Spain</aff><aff id="I7"><label>7</label>Pneumology Department, Hospital Universitario Marques de Valdecilla, School of Medicine, University of Cantabria, Av. Valdecilla s/n, 39008, Santander, Spain</aff><aff id="I8"><label>8</label>Endocrinology Department, Hospital Universitario Marques de Valdecilla, School of Medicine, University of Cantabria, Av. Valdecilla s/n, 39008, Santander, Spain</aff><aff id="I9"><label>9</label>Department of Molecular Biology, University of Cantabria, Avda. Cardenal Herrera Oria s/n, 39011, Santander, Spain</aff><aff id="I10"><label>10</label>General Surgery Department, Hospital Universitario Marques de Valdecilla, School of Medicine, University of Cantabria, Av. Valdecilla s/n, 39008, Santander, Spain</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>9</day><month>11</month><year>2012</year></pub-date><volume>12</volume><fpage>292</fpage><lpage>292</lpage><history><date date-type="received"><day>24</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>7</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Fari&#x000f1;as et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Fari&#x000f1;as et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2334/12/292"/><abstract><sec><title>Background</title><p>Consultation to infectious diseases specialists (ID), although not always performed by treating physicians, is part of hospital&#x02019;s daily practice. This study analyses adherence by treating physicians to written ID recommendations (inserted in clinical records) and its effect on outcome in hospitalized antibiotic-treated patients in a tertiary hospital in Spain.</p></sec><sec><title>Methods</title><p>A prospective, randomized, one-year study was performed. Patients receiving intravenous antimicrobial therapy prescribed by treating physicians for 3 days were identified and randomised to intervention (insertion of written ID recommendations in clinical records) or non-intervention. Appropriateness of empirical treatments (by treating physicians) was classified as adequate, inadequate or unnecessary. In the intervention group, adherence to recommendations was classified as complete, partial or non-adherence.</p></sec><sec><title>Results</title><p>A total of 1173 patients were included, 602 in the non-intervention and 571 in the intervention group [199 (34.9%) showing complete adherence, 141 (24.7%) partial adherence and 231 (40.5%) non-adherence to recommendations]. In the multivariate analysis for adherence (R<sup>2</sup> Cox=0.065, p=0.009), non-adherence was associated with prolonged antibiotic prophylaxis (p=0.004; OR=0.37, 95%CI=0.19-0.72). In the multivariate analysis for clinical failure (R<sup>2</sup> Cox=0.126, p&#x0003c;0.001), Charlson index (p&#x0003c;0.001; OR=1.19, 95%CI=1.10-1.28), malnutrition (p=0.006; OR=2.00, 95%CI=1.22-3.26), nosocomial infection (p&#x0003c;0.001; OR=4.12, 95%CI=2.27-7.48) and length of hospitalization (p&#x0003c;0.001; OR=1.01, 95%CI=1.01-1.02) were positively associated with failure, while complete adherence (p=0.001; OR=0.35, 95%CI=0.19-0.64) and adequate initial treatment (p=0.010; OR=0.39, 95%CI=0.19-0.80) were negatively associated.</p></sec><sec><title>Conclusions</title><p>Adherence to ID recommendations by treating physicians was associated with favorable outcome, in turn associated with shortened length of hospitalization. This may have important health&#x02013;economic benefits and stimulates further investigation.</p></sec><sec><title>Trial registration</title><p>Current Controlled Trials ISRCTN83234896. 
<ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/isrctn/sample_documentation.asp">http://www.controlled-trials.com/isrctn/sample_documentation.asp</ext-link></p></sec></abstract><kwd-group><kwd>Infectious diseases specialists</kwd><kwd>Antibiotic intervention</kwd><kwd>Antibiotic use</kwd><kwd>Antibiotic management</kwd><kwd>Antimicrobial stewardship</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Antibiotics account for one-third of hospital&#x02019;s pharmacy budget, with between 25% and 50% hospitalized patients receiving antibiotics 
[<xref ref-type="bibr" rid="B1">1</xref>]. In hospitals, nearly all physicians prescribe antibiotics, and their prescriptions are influenced by characteristics of patient population, physician&#x02019;s prescribing habits and local resistance patterns 
[<xref ref-type="bibr" rid="B2">2</xref>]. Inappropriate use of antibiotics results in a variety of adverse outcomes: narrow coverage increases the risk of therapeutic failure whereas broad coverage increases the risk of superinfection 
[<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Antimicrobial stewardship by multidisciplinary teams 
[<xref ref-type="bibr" rid="B4">4</xref>] (including preventive medicine specialists, pharmacists, pharmacologists, microbiologists, infectious diseases specialists -IDs- and infection control nurses) is of increasing importance in the last decades due to the growing problem of nosocomial infections and resistance to antibiotics 
[<xref ref-type="bibr" rid="B5">5</xref>]. This together with the increasing proportion of hospitalized elderly patients with co-morbidities (that more frequently suffer infections) have contributed to the demand for more infectious disease services 
[<xref ref-type="bibr" rid="B6">6</xref>]. IDs can improve effectiveness by recommending a more appropriate antibiotic use 
[<xref ref-type="bibr" rid="B7">7</xref>], and their positive impact on patient care and infection control has been demonstrated 
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. The effectiveness of infectious disease consultations depends not only on clinically astute recommendations, but also on the adherence to them, since without it even the best recommendations are rendered ineffective 
[<xref ref-type="bibr" rid="B10">10</xref>]. Consultation to IDs, although not always performed by treating physicians, is part of hospital&#x02019;s daily practice. The easy and rapid access to IDs has been identified as important factor facilitating consultation instead of seeking other sources of information, which are more time-consuming 
[<xref ref-type="bibr" rid="B7">7</xref>]. For this reason insertion of written ID recommendations in clinical records seems an strategy to be considered for rapid access to ID recommendations by treating physicians.</p><p>The aim of the present study was to investigate adherence by treating physicians to written ID recommendations inserted in clinical records and the potential influence that this adherence had on clinical outcome in hospitalized intravenous antibiotic-treated patients in a tertiary university teaching hospital in Spain.</p><sec><title>Patients and methods</title><p>A prospective, randomized, controlled study was carried out from January 2008 to December 2008 in the Hospital Universitario Marques de Valdecilla, Santander, Spain, a tertiary universitary hospital with 874 beds. The study protocol was approved by the Ethics Committee of the Autonomous Community of Cantabria (IFIMAV, Spain), the Fondo de Investigaciones Sanitarias [Registered number: FIS PI06/90094], and the Instituto de Formaci&#x000f3;n e Investigaci&#x000f3;n Marqu&#x000e9;s de Valdecilla (IFIMAV) [Registered number: API 06/03]. The patient&#x02019;s informed consent was waived because the study was directed to treating physicians, not to patients, since the primary objective of the study was to assess adherence by treating physicians to ID recommendations using a new method described below. Potential influence of adherence by treating physicians on patient's outcomes was only secondarily assessed. The possibility of ID consultations is part of normal practice in the hospital, and as in routine practice, treating physicians participating in the study could ask for ID oral consultation at any time.</p><p>Patients admitted in General Surgery, Pneumology and Endocrinology departments that were receiving intravenous antimicrobial therapy prescribed by their responsible physicians for 3 days were identified by the Pharmacy department. The ID team was daily contacted and patients were randomised by groups (stratified randomization by clinical units) to intervention or non-intervention using the EPIDAT 3.1 programme (Direcci&#x000f3;n Xeral de Sa&#x000fa;de P&#x000fa;blica, Xunta de Galicia &#x00026; Organizaci&#x000f3;n Panamericana de la Salud. Santiago de Compostela, Coru&#x000f1;a, Spain, 2003). Interventions consisted of insertion in medical records of written treatment recommendations by an ID physician based on International 
[<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>] and Spanish 
[<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>] treatment guidelines adapted to local data on antimicrobial susceptibility after examination of patients, clinical records and microbiological data (if any) for each patient in the intervention group. Written recommendations (in specifically designed study forms) were inserted in the patient&#x02019;s records in order to make it available to treating physicians, with a statement indicating availability for oral consultation if desired. Consultation was also available as part of daily practice for physicians treating patients in the non-intervention group (without insertion of written recommendations), but in the case of consultation the patient was withdrawn from the study. Paediatric patients, chronic dialysis patients, those receiving oral antibiotic therapy and those in which a member of the ID department had prescribed the initial antimicrobial regimen, were excluded.</p><p>Demographic and clinical data (including comorbidities), reason for antibiotic administration, regimen of antibiotic treatment, imaging and microbiological data, and microbiological and clinical outcomes were recorded both for patients in the intervention and non-intervention groups. The Charlson comorbidity index unadjusted by age 
[<xref ref-type="bibr" rid="B17">17</xref>] (age and sex were considered as separate variables), and the McCabe score 
[<xref ref-type="bibr" rid="B18">18</xref>] were calculated. Regimens of antibiotic treatment were classified as empirical, microbiologically-based or prolonged prophylaxis (antibiotic prophylaxis administered for &#x0003e;24 hours). Length of hospitalization (time from admission to discharge/death) was calculated. Patients with definite infection were those who met clinical criteria for infection with or without microbiological documentation. Infection was considered as nosocomial when signs/symptoms initiated 48-72h after admission and as healthcare-associated infection if infection occurred in patients who came from nursing homes or chronic care centres, had domiciliary hospitalization, had attended the hospital for oncological chemotherapy or had been hospitalized within the previous 30 days.</p><p>The appropriateness of empirical treatments prescribed by treating physicians (physicians of the primary service) was assessed and treatments were classified as adequate (agree with antibiotic choice, dosage, dosing interval and duration of treatment) or inadequate. Treatments were considered inadequate when one or several criteria following the Erbay&#x02019;s modification 
[<xref ref-type="bibr" rid="B19">19</xref>] of Kunin&#x02019;s criteria 
[<xref ref-type="bibr" rid="B20">20</xref>] were met. When IDs disagreed with the need for an antibiotic, treatments were classified as &#x0201c;unnecessary&#x0201d; by assigning a new category and thus eliminating this criterion from the Erbay&#x02019;s category &#x0201c;inadequate&#x0201d;. In the intervention group, the degree of adherence to intervention was assessed at day +7 and +10 (from initiation of intravenous antibiotic treatment) and classified as complete (administration within 24h after consultation of the recommended antibiotic therapy with deviations lower than 20% for the dose and lower than &#x000b1;30% for treatment duration), partial (administration of the recommended antibiotic therapy with deviations greater than 20% for the dose and/or greater than &#x000b1;30% for duration and/or initiation between 24h and 48h after consultation) or non-adherence (non prescription of the recommended regimen or initiation after 48h from consultation). When the recommended duration of treatment was longer than 10 days, adherence was assessed at discharge.</p><p>Patients were followed during hospitalisation and at discharge they were clinically evaluated as &#x0201c;clinical success&#x0201d; (cure or improvement) or &#x0201c;clinical failure&#x0201d; (absence of improvement, worsening or death during hospitalization). Cure was considered when patients were discharged from the hospital with resolution of acute signs and symptoms of infection and improvement when patients were discharged from the hospital with oral antibiotic treatment. Patients with an initial positive culture and at least one follow-up culture were considered microbiologically evaluable and were evaluated as &#x0201c;microbiological success&#x0201d; (eradication) or &#x0201c;microbiological failure&#x0201d; (persistence or superinfection) at discharge.</p><p>Comparisons between proportions were performed by the &#x003c7;2 test and the Fisher&#x02019;s exact test, when necessary. For quantitative variables, since data did not showed normality in the Kolmogorov-Smirnoff test, the Kruskal-Wallis and Mann&#x02013;Whitney tests, when necessary, were used. Bivariate analyses were performed comparing all variables between the group of patients with treatment showing adherence (complete adherence or complete plus partial adherence) versus those showing non-adherence, as well as between the group of patients showing clinical success versus those showing clinical failure. In order to avoid false associations in multiple comparisons in the bivariate analyses, the Bonferroni correction was applied and the p&#x0003c;0.001 was considered statistically significant to minimize type 1 error.Two different logistic regression models (step&#x02013;wise procedure) were performed: one using &#x0201c;adherence&#x0201d; as dependent variable and another using &#x0201c;clinical failure&#x0201d;. In both multivariate analyses, independent variables were those showing differences (p&#x02264;0.1) in the previous bivariate analyses performed. In the multivariate analysis using &#x0201c;clinical failure&#x0201d; as dependent variable, adherence (both considered as complete adherence and as complete + partial adherence) was one of the independent variables introduced. Interactions and linear dependence between independent variables were previously controlled. Statistical analyses were performed using SPSS v 18 programme (SPSS Inc, Chicago IL). The models showing the highest R<sup>2</sup> were considered.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Disposition of patients</title><p>A total of 1266 adult patients receiving intravenous antibiotic treatment for 3 days were identified by the Pharmacy department. Of them, 1185 patients were randomized and 1173 antibiotic-treated patients were finally considered, 571 patients in the intervention group and 602 patients in the non-intervention group. Figure&#x02009;
<xref ref-type="fig" rid="F1">1</xref> shows the study flow-chart including reasons for exclusion and withdrawns. Among the 571 patients in the intervention group, 199 (34.9%) showed complete adherence to the recommendation, 141 (24.7%) partial adherence and 231 (40.5%) non-adherence.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Study flow-chart.</p></caption><graphic xlink:href="1471-2334-12-292-1"/></fig></sec><sec><title>Baseline demographic and clinical characteristics</title><p>Table&#x02009;
<xref ref-type="table" rid="T1">1</xref> shows baseline demographic data, comorbidity and prognostic indices of patients included in the study distributed by study groups. Comorbidities present in &#x0003e;10% study patients were: previous surgery (62.0%), malignancies (41.2%), diabetes mellitus (39.7%), heart disease (38.5%), chronic respiratory insufficiency (32.9%), renal insufficiency (30.6%), immunosuppressive therapy (17.8%), smokers (14.1%) and alcohol intake (12.1%), without significant differences between the intervention and the non-intervention groups. The group of patients with intervention showed higher, although non-significant, Charlson index (p=0.006). When comparing groups by adherence to recommendations (complete versus partial versus non-adherence) significant differences were not found. The percentage of smokers (23.6% versus 13.4%, p=0.006) and of patients with chronic respiratory insufficiency (45.2% versus 32.9%, p=0.009) was non-significantly higher in the group of patients with complete adherence versus non-adherence. In the same way the percentage of patients with previous surgery was also non-significantly higher (44.2% versus 59.3%, p=0.002) in the non-adherence group.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline demographic and clinical characteristics for each group </p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="4" align="left" valign="bottom"><bold>Intervention</bold><hr/></th><th align="center" valign="bottom"><bold>Non intervention</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="char" char="."><bold>Complete</bold></th><th align="char" char="."><bold>Partial</bold></th><th align="char" char="."><bold>Non adherence</bold></th><th align="char" char="("><bold>Total</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">N<hr/></td><td align="char" valign="bottom" char=".">199<hr/></td><td align="char" valign="bottom" char=".">141<hr/></td><td align="char" valign="bottom" char=".">231<hr/></td><td align="char" valign="bottom" char="(">571<hr/></td><td align="char" valign="bottom" char="(">602<hr/></td></tr><tr><td align="left" valign="bottom">Age (years; mean &#x000b1; SD)<hr/></td><td align="char" valign="bottom" char=".">64.9 &#x000b1; 17.6<hr/></td><td align="char" valign="bottom" char=".">64.7 &#x000b1; 15.8<hr/></td><td align="char" valign="bottom" char=".">64.8 &#x000b1; 17.8<hr/></td><td align="char" valign="bottom" char="(">64.8 &#x000b1; 17.2<hr/></td><td align="char" valign="bottom" char="(">65.0 &#x000b1; 17.2<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;&#x02264;65<hr/></td><td align="char" valign="bottom" char=".">90 (45.2)<hr/></td><td align="char" valign="bottom" char=".">69 (48.9)<hr/></td><td align="char" valign="bottom" char=".">99 (42.8)<hr/></td><td align="char" valign="bottom" char="(">258 (45.2)<hr/></td><td align="char" valign="bottom" char="(">272 (45.2)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;66-75<hr/></td><td align="char" valign="bottom" char=".">38 (19.1)<hr/></td><td align="char" valign="bottom" char=".">33 (23.4)<hr/></td><td align="char" valign="bottom" char=".">60 (26.0)<hr/></td><td align="char" valign="bottom" char="(">131 (22.9)<hr/></td><td align="char" valign="bottom" char="(">128 (21.3)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;&#x0003e;75<hr/></td><td align="char" valign="bottom" char=".">71 (35.7)<hr/></td><td align="char" valign="bottom" char=".">39 (27.7)<hr/></td><td align="char" valign="bottom" char=".">72 (31.2)<hr/></td><td align="char" valign="bottom" char="(">182 (31.9)<hr/></td><td align="char" valign="bottom" char="(">202 (33.5)<hr/></td></tr><tr><td align="left" valign="bottom">Males<hr/></td><td align="char" valign="bottom" char=".">127 (63.8)<hr/></td><td align="char" valign="bottom" char=".">91 (64.5)<hr/></td><td align="char" valign="bottom" char=".">142 (61.5)<hr/></td><td align="char" valign="bottom" char="(">360 (63.0)<hr/></td><td align="char" valign="bottom" char="(">375 (62.3)<hr/></td></tr><tr><td align="left" valign="bottom">Coming from healthcare facilities<hr/></td><td align="char" valign="bottom" char=".">47 (23.6)<hr/></td><td align="char" valign="bottom" char=".">26 (18.4)<hr/></td><td align="char" valign="bottom" char=".">63 (27.3)<hr/></td><td align="char" valign="bottom" char="(">136 (23.8)<hr/></td><td align="char" valign="bottom" char="(">103 (17.1)<hr/></td></tr><tr><td align="left" valign="bottom">Prior hospitalization (previous 30 days)<hr/></td><td align="char" valign="bottom" char=".">56 (28.1)<hr/></td><td align="char" valign="bottom" char=".">41 (29.1)<hr/></td><td align="char" valign="bottom" char=".">76 (32.9)<hr/></td><td align="char" valign="bottom" char="(">173 (30.3)<hr/></td><td align="char" valign="bottom" char="(">150 (24.9)<hr/></td></tr><tr><td align="left" valign="bottom">Prior hospitalization (previous 90 days)<hr/></td><td align="char" valign="bottom" char=".">81 (40.7)<hr/></td><td align="char" valign="bottom" char=".">53 (37.6)<hr/></td><td align="char" valign="bottom" char=".">89 (38.5)<hr/></td><td align="char" valign="bottom" char="(">223 (39.1)<hr/></td><td align="char" valign="bottom" char="(">184 (30.6)<hr/></td></tr><tr><td align="left" valign="bottom">Ward of admission (Surgical)<hr/></td><td align="char" valign="bottom" char=".">102 (51.3)<hr/></td><td align="char" valign="bottom" char=".">89 (63.1)<hr/></td><td align="char" valign="bottom" char=".">158 (68.4) <sup>a</sup><hr/></td><td align="char" valign="bottom" char="(">349 (61.1)<hr/></td><td align="char" valign="bottom" char="(">423 (70.3)<hr/></td></tr><tr><td align="left" valign="bottom">Charlson (mean &#x000b1; SD)<hr/></td><td align="char" valign="bottom" char=".">2.26 &#x000b1; 2.04<hr/></td><td align="char" valign="bottom" char=".">2.74 &#x000b1; 2.38<hr/></td><td align="char" valign="bottom" char=".">2.38 &#x000b1; 2.15<hr/></td><td align="char" valign="bottom" char="(">2.43 &#x000b1; 2.18<hr/></td><td align="char" valign="bottom" char="(">2. 09 &#x000b1; 2.10<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;&#x02264;1<hr/></td><td align="char" valign="bottom" char=".">82 (41.2)<hr/></td><td align="char" valign="bottom" char=".">53 (37.6)<hr/></td><td align="char" valign="bottom" char=".">90 (39.0)<hr/></td><td align="char" valign="bottom" char="(">225 (39.4)<hr/></td><td align="char" valign="bottom" char="(">293 (48.7)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;2<hr/></td><td align="char" valign="bottom" char=".">44 (22.1)<hr/></td><td align="char" valign="bottom" char=".">23 (16.3)<hr/></td><td align="char" valign="bottom" char=".">42 (18.2)<hr/></td><td align="char" valign="bottom" char="(">109 (19.1)<hr/></td><td align="char" valign="bottom" char="(">111 (18.4)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;3<hr/></td><td align="char" valign="bottom" char=".">34 (17.1)<hr/></td><td align="char" valign="bottom" char=".">20 (14.2)<hr/></td><td align="char" valign="bottom" char=".">36 (15.6)<hr/></td><td align="char" valign="bottom" char="(">90 (15.8)<hr/></td><td align="char" valign="bottom" char="(">69 (11.5)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;&#x02265;4<hr/></td><td align="char" valign="bottom" char=".">39 (19.6)<hr/></td><td align="char" valign="bottom" char=".">45 (31.9)<hr/></td><td align="char" valign="bottom" char=".">63 (27.3)<hr/></td><td align="char" valign="bottom" char="(">147 (25.7)<hr/></td><td align="char" valign="bottom" char="(">129 (21.4)<hr/></td></tr><tr><td align="left" valign="bottom">Mc Cabe (Fatal)<hr/></td><td align="char" valign="bottom" char=".">64 (32.2)<hr/></td><td align="char" valign="bottom" char=".">55 (39.0)<hr/></td><td align="char" valign="bottom" char=".">72 (31.2)<hr/></td><td align="char" valign="bottom" char="(">191 (33.4)<hr/></td><td align="char" valign="bottom" char="(">201 (33.4)<hr/></td></tr><tr><td align="left">Reason for admission (infectious disease)</td><td align="char" char=".">102 (51.3)</td><td align="char" char=".">68 (48.2)</td><td align="char" char=".">111 (48.1)</td><td align="char" char="(">281 (49.2)</td><td align="char" char="(">299 (49.7)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>p&#x0003c;0.001 versus complete adherence. Data expressed as n (%) except where indicated.</p></table-wrap-foot></table-wrap><p>In relation to wards of admission, a significant higher percentage of patients admitted in surgical wards was found in the group with non-adherence (68.4% versus 51.3%, p&#x0003c;0.001).</p><p>Of the 1173 patients included, definitive infection was diagnosed in 913 (77.8%) patients, without differences in type and site of infections between groups. Community-acquired infections were the most frequent (597 out of 913, 65.4%) followed by nosocomial infections (277 out of 913, 30.3%). Healthcare associated infections only represented 4.3% (39 out of 913). By site of infection, lower respiratory tract infections were the most frequent (30.3%) followed by gastrointestinal infections (22.9%) and surgical site infections (22.1%).</p></sec><sec><title>Baseline microbiological data</title><p>Microbiological tests were significantly (p&#x0003c;0.001) more frequently requested in the group of patients with complete adherence versus those with non-adherence (Table&#x02009;
<xref ref-type="table" rid="T2">2</xref>). Of the 747 initial cultures requested, 402 (53.8%) were positive, with non-significantly higher percentage of positive cultures (59.3% versus 48.1% p=0.002) in the intervention group. Overall, <italic>Escherichia coli</italic> (22.9%), <italic>Streptococcus pneumoniae</italic> (12.2%) and <italic>Pseudomonas aeruginosa</italic> (10.2%) were the most frequent species isolated.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Microbiological tests [n (%)] and isolates (&#x0003e;10%) among those with positive cultures</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="4" align="left" valign="bottom"><bold>Intervention</bold><hr/></th><th align="center" valign="bottom"><bold>Non intervention</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>Complete</bold></th><th align="center"><bold>Partial</bold></th><th align="center"><bold>Non adherence</bold></th><th align="center"><bold>Total</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">N<hr/></td><td align="char" valign="bottom" char="(">199<hr/></td><td align="char" valign="bottom" char="(">141<hr/></td><td align="char" valign="bottom" char="(">231<hr/></td><td align="char" valign="bottom" char="(">571<hr/></td><td align="char" valign="bottom" char="(">602<hr/></td></tr><tr><td align="left" valign="bottom">Patients with no microbiological tests<hr/></td><td align="char" valign="bottom" char="(">42 (21.1)<hr/></td><td align="char" valign="bottom" char="(">35 (24.8)<hr/></td><td align="char" valign="bottom" char="(">86 (37.2) <sup>a</sup><hr/></td><td align="char" valign="bottom" char="(">163 (28.5)<hr/></td><td align="char" valign="bottom" char="(">212 (35.2)<hr/></td></tr><tr><td align="left" valign="bottom">Patients with serology<hr/></td><td align="char" valign="bottom" char="(">17 (8.5)<hr/></td><td align="char" valign="bottom" char="(">3 (2.1)<hr/></td><td align="char" valign="bottom" char="(">9 (3.9)<hr/></td><td align="char" valign="bottom" char="(">29 (5.1)<hr/></td><td align="char" valign="bottom" char="(">22 (3.7)<hr/></td></tr><tr><td align="left" valign="bottom">Patients with culture<hr/></td><td align="char" valign="bottom" char="(">140 (70.4)<hr/></td><td align="char" valign="bottom" char="(">103 (73.1)<hr/></td><td align="char" valign="bottom" char="(">136 (58.8)<hr/></td><td align="char" valign="bottom" char="(">379 (66.4)<hr/></td><td align="char" valign="bottom" char="(">368 (61.1)<hr/></td></tr><tr><td align="left" valign="bottom">Positive cultures<hr/></td><td align="char" valign="bottom" char="(">80 (57.1)<hr/></td><td align="char" valign="bottom" char="(">65 (63.1)<hr/></td><td align="char" valign="bottom" char="(">80 (58.8)<hr/></td><td align="char" valign="bottom" char="(">225 (59.3)<hr/></td><td align="char" valign="bottom" char="(">177 (48.1)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;<italic>E. coli</italic><hr/></td><td align="char" valign="bottom" char="(">16 (20.0)<hr/></td><td align="char" valign="bottom" char="(">17 (26.2)<hr/></td><td align="char" valign="bottom" char="(">16 (20.0)<hr/></td><td align="char" valign="bottom" char="(">49 (21.8)<hr/></td><td align="char" valign="bottom" char="(">43 (24.3)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;<italic>S. pneumoniae</italic><hr/></td><td align="char" valign="bottom" char="(">13 (16.3)<hr/></td><td align="char" valign="bottom" char="(">6 (9.2)<hr/></td><td align="char" valign="bottom" char="(">9 (11.3)<hr/></td><td align="char" valign="bottom" char="(">28 (12.4)<hr/></td><td align="char" valign="bottom" char="(">21 (11.9)<hr/></td></tr><tr><td align="left">&#x02003;&#x02003;<italic>P. aeruginosa</italic></td><td align="char" char="(">11 (13.8)</td><td align="char" char="(">7 (10.8)</td><td align="char" char="(">10 (12.5)</td><td align="char" char="(">28 (12.4)</td><td align="char" char="(">13 (7.3)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>p&#x0003c;0.001 versus complete adherence.</p></table-wrap-foot></table-wrap></sec><sec><title>Characteristics of antibiotic treatments prior to ID recommendations</title><p>Of the 1173 patients included, 209 (17.8%) patients received antibiotics as prolonged prophylaxis, with significantly higher percentage of patients receiving prophylaxis in the non-intervention group (Table&#x02009;
<xref ref-type="table" rid="T3">3</xref>). The percentage of initial treatments classified as adequate was significantly higher in the intervention versus non intervention group, in the complete versus partial adherence or versus non-adherence groups and in the partial adherence versus non-adherence group (Table&#x02009;
<xref ref-type="table" rid="T3">3</xref>). The most frequent reasons for classifying treatments as inadequate were inadequacy of treatment duration (48.8%) and lack of adequate dosage adjustment in patients with chronic renal or hepatic insufficiency (33.8%). Significant differences in the percentage of inadequate treatment duration were found between the intervention and non-intervention groups (38.4% versus 58.6%, p&#x0003c;0.001) and between complete adherence and non-adherence (16.1% versus 57.1%, p&#x0003c;0.001).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Characteristics of antibiotic treatment prescribed before intervention [n (%)]</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="4" align="left" valign="bottom"><bold>Intervention</bold><hr/></th><th align="center" valign="bottom"><bold>Non intervention</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>Complete</bold></th><th align="center"><bold>Partial</bold></th><th align="center"><bold>Non adherence</bold></th><th align="center"><bold>Total</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">N<hr/></td><td align="char" valign="bottom" char="(">199<hr/></td><td align="char" valign="bottom" char="(">141<hr/></td><td align="char" valign="bottom" char="(">231<hr/></td><td align="char" valign="bottom" char="(">571<hr/></td><td align="char" valign="bottom" char="(">602<hr/></td></tr><tr><td align="left" valign="bottom">Type of treatment<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Empirical<hr/></td><td align="char" valign="bottom" char="(">186 (93.5)<hr/></td><td align="char" valign="bottom" char="(">130 (92.2)<hr/></td><td align="char" valign="bottom" char="(">183 (79.2)<hr/></td><td align="char" valign="bottom" char="(">499 (87.4)<hr/></td><td align="char" valign="bottom" char="(">458 (76.1)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Prolonged Prophylaxis<hr/></td><td align="char" valign="bottom" char="(">13 (6.5)<hr/></td><td align="char" valign="bottom" char="(">10 (7.1)<hr/></td><td align="char" valign="bottom" char="(">45 (19.5) <sup>a</sup><hr/></td><td align="char" valign="bottom" char="(">68 (11.9)<hr/></td><td align="char" valign="bottom" char="(">141 (23.4) <sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Microbiologically-based<hr/></td><td align="char" valign="bottom" char="(">0 (0.0)<hr/></td><td align="char" valign="bottom" char="(">1 (0.7)<hr/></td><td align="char" valign="bottom" char="(">3 (1.3)<hr/></td><td align="char" valign="bottom" char="(">4 (0.7)<hr/></td><td align="char" valign="bottom" char="(">3 (0.5)<hr/></td></tr><tr><td align="left" valign="bottom">Antibiotic regimens including<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;One compound<hr/></td><td align="char" valign="bottom" char="(">119 (59.8)<hr/></td><td align="char" valign="bottom" char="(">93 (66.0)<hr/></td><td align="char" valign="bottom" char="(">170 (73.6)<hr/></td><td align="char" valign="bottom" char="(">382 (66.9)<hr/></td><td align="char" valign="bottom" char="(">451 (74.9)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Two or more compounds<hr/></td><td align="char" valign="bottom" char="(">80 (40.2)<hr/></td><td align="char" valign="bottom" char="(">48 (34.0)<hr/></td><td align="char" valign="bottom" char="(">61 (26.4)<hr/></td><td align="char" valign="bottom" char="(">189 (33.1)<hr/></td><td align="char" valign="bottom" char="(">151 (25.1)<hr/></td></tr><tr><td align="left" valign="bottom">Treatment initiation in Emergency room<hr/></td><td align="char" valign="bottom" char="(">56 (28.1)<hr/></td><td align="char" valign="bottom" char="(">40 (28.4)<hr/></td><td align="char" valign="bottom" char="(">65 (28.1)<hr/></td><td align="char" valign="bottom" char="(">161 (28.2)<hr/></td><td align="char" valign="bottom" char="(">97 (16.1) <sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">Treatment evaluation (initial)<hr/></td><td align="char" valign="bottom" char="(">199<hr/></td><td align="char" valign="bottom" char="(">141<hr/></td><td align="char" valign="bottom" char="(">231<hr/></td><td align="char" valign="bottom" char="(">571<hr/></td><td align="char" valign="bottom" char="(">602<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Adequate<hr/></td><td align="char" valign="bottom" char="(">70 (35.2)<hr/></td><td align="char" valign="bottom" char="(">22 (15.6) <sup>a</sup><hr/></td><td align="char" valign="bottom" char="(">4 (1.7) <sup>a,c</sup><hr/></td><td align="char" valign="bottom" char="(">96 (16.8)<hr/></td><td align="char" valign="bottom" char="(">60 (10.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Inadequate<hr/></td><td align="char" valign="bottom" char="(">129 (64.8)<hr/></td><td align="char" valign="bottom" char="(">115 (81.6) <sup>a</sup><hr/></td><td align="char" valign="bottom" char="(">222 (96.1) <sup>a,c</sup><hr/></td><td align="char" valign="bottom" char="(">466 (81.6)<hr/></td><td align="char" valign="bottom" char="(">531 (88.2)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Unnecessary<hr/></td><td align="char" valign="bottom" char="(">0 (0.0)<hr/></td><td align="char" valign="bottom" char="(">4 (2.8)<hr/></td><td align="char" valign="bottom" char="(">5 (2.2)<hr/></td><td align="char" valign="bottom" char="(">9 (1.6)<hr/></td><td align="char" valign="bottom" char="(">11 (1.8)<hr/></td></tr><tr><td align="left">Modification of initial treatment</td><td align="char" char="(">129 (64.8)</td><td align="char" char="(">52 (36.9) <sup>a</sup></td><td align="char" char="(">33 (14.3) <sup>a,c</sup></td><td align="char" char="(">214 (37.5)</td><td align="char" char="(">105 (17.4) <sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>p&#x0003c;0.001 versus complete adherence; <sup>b</sup>p&#x0003c;0.001 versus Total intervention; <sup>c</sup>p&#x0003c;0.001 versus partial adherence.</p></table-wrap-foot></table-wrap><p>Modifications of initial treatments were significantly (p&#x0003c;0.001) more frequent in the intervention group, and within this group, in the group of complete versus partial adherence or versus non-adherence and in the group of partial adherence versus non-adherence (Table&#x02009;
<xref ref-type="table" rid="T3">3</xref>).</p></sec><sec><title>Outcome</title><p>Table&#x02009;
<xref ref-type="table" rid="T4">4</xref> shows length of hospitalization and clinical and microbiological outcomes of patients included in the study distributed by study groups. Significantly (p&#x0003c;0.001) higher percentage of clinical success (cure + improvement) was found in the group of complete adherence (92.5%) versus non-adherence (80.1%) or versus the non-intervention group (81.9%). Mortality was 4.3%, without differences between groups. The percentage of patients showing microbiological eradication among the 190 microbiologically evaluable patients was significantly higher in the intervention group (41.9% versus 21.2%, p&#x0003c;0.001) and, within this group, in the group of complete adherence versus non-adherence (69.4% versus 20.0%, p&#x0003c;0.001).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Clinical and microbiological outcome [n (%)] of patients included in the study</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="4" align="left" valign="bottom"><bold>Intervention</bold><hr/></th><th align="center" valign="bottom"><bold>Non intervention</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>Complete</bold></th><th align="center"><bold>Partial</bold></th><th align="center"><bold>Non adherence</bold></th><th align="center"><bold>Total</bold></th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">N<hr/></td><td align="center" valign="bottom">199<hr/></td><td align="center" valign="bottom">141<hr/></td><td align="center" valign="bottom">231<hr/></td><td align="center" valign="bottom">571<hr/></td><td align="center" valign="bottom">602<hr/></td></tr><tr><td align="left" valign="bottom">Length of hospitalization (days; mean &#x000b1;SD)<hr/></td><td align="center" valign="bottom">24.1 &#x000b1; 29.3<hr/></td><td align="center" valign="bottom">26.5 &#x000b1; 24.3<hr/></td><td align="center" valign="bottom">20.2 &#x000b1; 18.8<hr/></td><td align="center" valign="bottom">23.1 &#x000b1; 24.3<hr/></td><td align="center" valign="bottom">20.3 &#x000b1; 33.8<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Clinical outcome</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Cure + improvement<hr/></td><td align="center" valign="bottom">184 (92.5)<hr/></td><td align="center" valign="bottom">121 (85.8)<hr/></td><td align="center" valign="bottom">185 (80.1) <sup>a</sup><hr/></td><td align="center" valign="bottom">490 (85.8)<hr/></td><td align="center" valign="bottom">493 (81.9) <sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02003;Death<hr/></td><td align="center" valign="bottom">4 (2.0)<hr/></td><td align="center" valign="bottom">5 (3.5)<hr/></td><td align="center" valign="bottom">12 (5.2)<hr/></td><td align="center" valign="bottom">21 (3.7)<hr/></td><td align="center" valign="bottom">30 (5.0)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Microbiological outcome</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">No. patients microbiologically evaluable<sup>b</sup><hr/></td><td align="center" valign="bottom">36 (18.1)<hr/></td><td align="center" valign="bottom">29 (20.6)<hr/></td><td align="center" valign="bottom">40 (17.3)<hr/></td><td align="center" valign="bottom">105 (18.4)<hr/></td><td align="center" valign="bottom">85 (14.1)<hr/></td></tr><tr><td align="left">&#x02003;&#x02003;Eradication</td><td align="center">25 (69.4)</td><td align="center">11 (37.9)</td><td align="center">8 (20.0) <sup>a</sup></td><td align="center">44 (41.9)</td><td align="center">18 (21.2) <sup>a,c</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>p&#x0003c;0.001 versus complete adherence; <sup>b</sup>patients with initial positive culture and at least one follow-up culture; <sup>c</sup>p&#x0003c;0.001 versus Total intervention.</p></table-wrap-foot></table-wrap></sec><sec><title>Factors associated with adherence and clinical outcome</title><p>The multivariate analysis using &#x0201c;adherence&#x0201d; as dependent variable was significant (R<sup>2</sup> Cox=0.065, p=0.009), with adherence negatively associated with prolonged prophylaxis (p=0.004; OR=0.37, 95%CI=0.19-0.72).</p><p>Table&#x02009;
<xref ref-type="table" rid="T5">5</xref> shows significant variables (p&#x0003c;0.1) in the bivariate analysis comparing patients showing success with those showing clinical failure. These variables were those included in the multivariate analysis using &#x0201c;clinical failure&#x0201d; as dependent variable and the results are shown in the Table. The model was significant (R<sup>2</sup> Cox=0.126, p&#x0003c;0.001), with Charlson index (p&#x0003c;0.001; OR=1.19, 95%CI=1.10-1.28), malnutrition (p=0.006; OR=2.00, 95%CI=1.22-3.26), nosocomial infection (p&#x0003c;0.001; OR=4.12, 95%CI=2.27-7.48) and length of hospitalization (p&#x0003c;0.001; OR=1.01, 95%CI=1.01-1.02) associated with clinical failure. Complete adherence (p=0.001; OR=0.35, 95%CI=0.19-0.64) and adequate initial treatment (p=0.010; OR=0.39, 95%CI=0.19-0.80) were negatively associated with clinical failure.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Factors predicting clinical failure</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th align="center" valign="bottom"><bold>Success</bold><hr/></th><th align="center" valign="bottom"><bold>Failure</bold><hr/></th><th align="center" valign="bottom"><bold>P</bold><hr/></th><th align="center" valign="bottom"><bold>OR</bold><hr/></th></tr><tr><th align="left">N</th><th align="center">983</th><th align="center">190</th><th align="center">Bivariate</th><th align="center">Multivariate</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (mean &#x000b1; SD)<hr/></td><td align="center" valign="bottom">64.1 &#x000b1; 17.6<hr/></td><td align="center" valign="bottom">68.9 &#x000b1; 14.7<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom">p= 0.100<hr/></td></tr><tr><td align="left" valign="bottom">Coming from healthcare facilities<hr/></td><td align="center" valign="bottom">183 (18.6)<hr/></td><td align="center" valign="bottom">56 (29.5)<hr/></td><td align="char" valign="bottom" char=".">0.001<hr/></td><td align="center" valign="bottom">p= 0.215<hr/></td></tr><tr><td align="left" valign="bottom">Prior hospitalization (previous 30 days)<hr/></td><td align="center" valign="bottom">255 (25.9)<hr/></td><td align="center" valign="bottom">68 (35.8)<hr/></td><td align="char" valign="bottom" char=".">0.005<hr/></td><td align="center" valign="bottom">p= 0.625<hr/></td></tr><tr><td align="left" valign="bottom">Charlson index<hr/></td><td align="center" valign="bottom">2.07 &#x000b1; 2.07<hr/></td><td align="center" valign="bottom">3.17 &#x000b1; 2.16<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom"><bold>1.19 (1.10-1.28) p&#x0003c;0.001</bold><hr/></td></tr><tr><td align="left" valign="bottom">Heart failure<hr/></td><td align="center" valign="bottom">358 (36.4)<hr/></td><td align="center" valign="bottom">94 (49.5)<hr/></td><td align="char" valign="bottom" char=".">0.001<hr/></td><td align="center" valign="bottom">p= 0.123<hr/></td></tr><tr><td align="left" valign="bottom">Renal insufficiency<hr/></td><td align="center" valign="bottom">281 (28.6)<hr/></td><td align="center" valign="bottom">86 (45.3)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom">p= 0.155<hr/></td></tr><tr><td align="left" valign="bottom">Diabetes<hr/></td><td align="center" valign="bottom">408 (41.5)<hr/></td><td align="center" valign="bottom">93 (48.9)<hr/></td><td align="char" valign="bottom" char=".">0.058<hr/></td><td align="center" valign="bottom">p= 0.744<hr/></td></tr><tr><td align="left" valign="bottom">Malignancies<hr/></td><td align="center" valign="bottom">384 (39.0)<hr/></td><td align="center" valign="bottom">104 (54.7)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom">p= 0.775<hr/></td></tr><tr><td align="left" valign="bottom">Immunosuppressive therapy<hr/></td><td align="center" valign="bottom">178 (18.1)<hr/></td><td align="center" valign="bottom">47 (24.7)<hr/></td><td align="char" valign="bottom" char=".">0.034<hr/></td><td align="center" valign="bottom">p= 0.262<hr/></td></tr><tr><td align="left" valign="bottom">Malnutrition<hr/></td><td align="center" valign="bottom">74 (7.5)<hr/></td><td align="center" valign="bottom">34 (17.9)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom"><bold>2.00 (1.22-3.26) p=0.006</bold><hr/></td></tr><tr><td align="left" valign="bottom">Nosocomial infection<hr/></td><td align="center" valign="bottom">187 (25.3)<hr/></td><td align="center" valign="bottom">88 (51.8)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom"><bold>4.12 (2.27-7.48) p&#x0003c;0.001</bold><hr/></td></tr><tr><td align="left" valign="bottom">Microbiological tests<hr/></td><td align="center" valign="bottom">652 (66.3)<hr/></td><td align="center" valign="bottom">160 (84.2)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom">p= 0.020<hr/></td></tr><tr><td align="left" valign="bottom">Complete adherence<hr/></td><td align="center" valign="bottom">184 (18.7)<hr/></td><td align="center" valign="bottom">15 (7.9)<hr/></td><td align="char" valign="bottom" char=".">0.001<hr/></td><td align="center" valign="bottom"><bold>0.35 (0.19-0.64) p=0.001</bold><hr/></td></tr><tr><td align="left" valign="bottom">Treatment initiated in Emergency room<hr/></td><td align="center" valign="bottom">777 (79.0)<hr/></td><td align="center" valign="bottom">138 (72.6)<hr/></td><td align="char" valign="bottom" char=".">0.051<hr/></td><td align="center" valign="bottom">p= 0.023<hr/></td></tr><tr><td align="left" valign="bottom">Adequate initial treatment<hr/></td><td align="center" valign="bottom">147 (15.0)<hr/></td><td align="center" valign="bottom">9 (4.7)<hr/></td><td align="char" valign="bottom" char=".">&#x0003c;0.001<hr/></td><td align="center" valign="bottom"><bold>0.39 (0.19-0.80) p=0.010</bold><hr/></td></tr><tr><td align="left" valign="bottom">Modification of initial treatment<hr/></td><td align="center" valign="bottom">306 (31.1)<hr/></td><td align="center" valign="bottom">43 (22.6)<hr/></td><td align="char" valign="bottom" char=".">0.019<hr/></td><td align="center" valign="bottom">p= 0.140<hr/></td></tr><tr><td align="left">Length of hospitalization</td><td align="center">18.9 (27.0)</td><td align="center">36.3 (37.4)</td><td align="char" char=".">&#x0003c;0.001</td><td align="center"><bold>1.01 (1.01-1.02) p&#x0003c;0.001</bold></td></tr></tbody></table><table-wrap-foot><p>It shows only significant variables in the bivariate analysis. &#x0201c;Clinical failure&#x0201d; was used as dependent variable.</p></table-wrap-foot></table-wrap><p>When the multivariate analysis was performed including complete plus partial adherence as independent variable (instead of complete adherence), the multivariate analysis was also significant (identical R<sup>2</sup> Cox) with the same variables positively or negatively associated with clinical failure. In the group of patients showing clinical success, complete + partial adherence was 31.0% while it was 18.4% among patients showing clinical failure. Complete + partial adherence was negatively associated with clinical failure (p&#x0003c;0.001; OR=0.43, 95%CI=0.28-0.67).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Most ID specialists believe that it is evident that their care is valuable, although there are few published studies on how frequently their recommendations are followed, or clinical consequences of following them 
[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Antimicrobial stewardship advocates the use of the most suitable antibiotic in the context of the presenting clinical condition and specific patient, and its success rely on coordination and collaboration between healthcare professionals to ensure consistency in approach, shared knowledge and widespread diffusion of practice 
[<xref ref-type="bibr" rid="B4">4</xref>]. Among strategies that have been used to decrease injudicious antimicrobial use, streamlining involves expert review of patient&#x02019;s antimicrobial regimens making recommendations to their providers about stopping or narrowing therapy 
[<xref ref-type="bibr" rid="B3">3</xref>]. However streamlining is applied after antimicrobial therapies have been initiated, allowing some degree of inappropriate exposure in addition to the potential limitation of effectiveness derived from the voluntary nature of its compliance 
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p><p>There is uncertainty about factors affecting adherence to recommendations 
[<xref ref-type="bibr" rid="B10">10</xref>]. In the present study, adherence (complete plus partial) was 59.5% or even lower if we consider only patients with complete adherence (34.9%). Although the percentage of complete + partial adherence is within the frame of 53% to 90% reported in the literature 
[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B23">23</xref>], complete adherence was lower. This low adherence in our study is worrying and can be related to the fact that eligible patients were identified when they were receiving antibiotic treatment for 3 days, a fact favoring not to follow recommendations in those patients with early favorable responses. In the multivariate analysis only prolonged prophylaxis was significantly associated with non-adherence. This contrast with the idea of expecting more requests from surgical units since they are less experienced with infectious diseases 
[<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Although the impact of infectious diseases consultations on actual patient management is difficult to assess 
[<xref ref-type="bibr" rid="B6">6</xref>], several studies have shown that consultations optimize antibiotic use in patients receiving intravenous antimicrobials and are cost-effective 
[<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. In the present study the group of patients with complete adherence to recommendations showed significant higher clinical success and eradication among microbiologically evaluable patients. Not surprisingly, Charlson index, malnutrition and nosocomial infections were the variables significantly associated with clinical failure in the multivariate analysis, but more importantly, adequate initial treatment and adherence to recommendations were negatively associated. These last factors are those that could be influenced by IDs in daily practice. In addition, microbiological tests were more frequently requested in patients randomized to intervention, with higher percentage of positive cultures, suggesting that ID consultation in addition to antibiotic advice also consciously or unconsciously influenced test request practices, and possibly led to more appropriate selection of sites for microbiological tests. These findings in patients receiving intravenous antibiotic therapy show that ID consultations not only improve patient&#x02019;s outcome but may also result in substantial cost reductions since clinical failure was significantly associated with larger length of hospitalization. Decreasing the hospital length of stay by promoting earlier hospital discharge significantly reduce overall costs and increase the efficiency and cost-effectiveness of the hospital 
[<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Several study limitations should be taken into consideration when extrapolating results to other settings since this study was performed in a single hospital, with participation of reduced number of specific wards, and only considering the subset of hospitalized patients receiving at least 3 days of intravenous antibiotic therapy. Probably local medical routines (differences in IDs daily practice) could influence extrapolations to other settings.</p><p>In conclusion, the method used for intervention (written recommendations inserted in clinical records 3 days after initiation of intravenous therapy) did not achieved a high degree of adherence despite this method made recommendations easily available to treating physicians. It has been reported that direct, personal communication 
[<xref ref-type="bibr" rid="B27">27</xref>] or the presence at patient&#x02019;s bedside of ID specialists 
[<xref ref-type="bibr" rid="B28">28</xref>] would dramatically improved adherence to recommendations, although this is not always possible in daily practice. Regardless the low adherence in the present study, the results showed that adherence to recommendations were associated with favorable clinical and microbiological outcomes and shortened length of hospitalization. The results of the present study stress the importance of adherence (without it even the best recommendations are rendered ineffective) 
[<xref ref-type="bibr" rid="B10">10</xref>] and suggest important health&#x02013;economic benefits. This stimulates further investigation in this field, with different methodologies and specific groups of patients, since as has been indicated, the need for physician expertise and intervention has never been more apparent than at the present time 
[<xref ref-type="bibr" rid="B29">29</xref>].</p></sec><sec><title>Abbreviation</title><p>IDs: Infectious Diseases specialists.</p></sec><sec><title>Competing interests</title><p>G. Saravia has received an educational grant from the Instituto de Formaci&#x000f3;n e Investigaci&#x000f3;n Marqu&#x000e9;s de Valdecilla (IFIMAV) for this study. All other authors: none to declare.</p></sec><sec><title>Authors&#x02019; contributions</title><p>Conceived and designed the study: M-CF, NB, CF-A, RA, J-AA, LM-M, MG-F. Collection of data: GS, JC-M, J-JM-G. Analyzed the data: M-CF, CF-A, LA. Wrote the paper: M-CF, LA. Reviewed and approved the manuscript: M-CF, GS, JC-M, NB, J-JM-G, CF-A, LA, RA, J-AA, LM-M, MG-F.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/12/292/prepub">http://www.biomedcentral.com/1471-2334/12/292/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>Parts of this study were presented at 50<sup>th</sup> ICAAC (Boston, September 2010; Abstract K-946), XIV Congreso SEIMC (Barcelona, May 2010; Abstract 647) and 22<sup>nd</sup> ECCMID (London, 31 March- 3 April, 2012; Abstract P1064). The authors are in debt with J.D. Garc&#x000ed;a-Palomo<sup>&#x02020;</sup> (Infectious Diseases Unit, H. Universitario Marques de Valdecilla, Santander, Spain) for his contribution to the study design and data analysis, with M.J. Gimenez (Microbiology Dpt., School of Medicine, Univ. Complutense, Madrid, Spain) for her critical review of the manuscript, with J.J. Granizo (Grana Datos SL, Madrid, Spain) for his help in the statistical analysis, and with M.T. Garc&#x000ed;a-Poladura for her technical assistance. This work was supported in part by unrestricted educational grants from the Fondo de Investigaciones Sanitarias [FIS PI06/90094], and Instituto de Formaci&#x000f3;n e Investigaci&#x000f3;n Marqu&#x000e9;s de Valdecilla (IFIMAV) [API 06/03].</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Ansari</surname><given-names>F</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Nathwani</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>G</given-names></name><name><surname>Ogston</surname><given-names>S</given-names></name><name><surname>Ramsay</surname><given-names>C</given-names></name><name><surname>Davey</surname><given-names>P</given-names></name><article-title>Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>52</volume><fpage>842</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg459</pub-id><pub-id pub-id-type="pmid">14563900</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Saizy-Callaert</surname><given-names>S</given-names></name><name><surname>Causse</surname><given-names>R</given-names></name><name><surname>Furhman</surname><given-names>C</given-names></name><name><surname>Le Paih</surname><given-names>MF</given-names></name><name><surname>Th&#x000e9;bault</surname><given-names>A</given-names></name><name><surname>Choua&#x000ef;d</surname><given-names>C</given-names></name><article-title>Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital</article-title><source>J Hosp Infect</source><year>2003</year><volume>53</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1053/jhin.2002.1307</pub-id><pub-id pub-id-type="pmid">12623317</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gross</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>AS</given-names></name><name><surname>Kinky</surname><given-names>DE</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Gibson</surname><given-names>GA</given-names></name><name><surname>Fishman</surname><given-names>NO</given-names></name><article-title>Impact of a hospital-based antimicrobial management program on clinical and economic outcomes</article-title><source>Clin Infect Dis</source><year>2001</year><volume>33</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1086/321880</pub-id><pub-id pub-id-type="pmid">11438891</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Charani</surname><given-names>E</given-names></name><name><surname>Cooke</surname><given-names>J</given-names></name><name><surname>Holmes</surname><given-names>A</given-names></name><article-title>Antibiotic stewardship programmes&#x02014;what&#x02019;s missing?</article-title><source>J Antimicrob Chemother</source><year>2010</year><volume>65</volume><fpage>2275</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq357</pub-id><pub-id pub-id-type="pmid">20851812</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Owens</surname><given-names>RC</given-names><suffix>Jr</suffix></name><article-title>Antimicrobial stewardship: concepts and strategies in the 21st century</article-title><source>Diagn Microbiol Infect Dis</source><year>2008</year><volume>61</volume><fpage>110</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2008.02.012</pub-id><pub-id pub-id-type="pmid">18384997</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Schlesinger</surname><given-names>Y</given-names></name><name><surname>Paltiel</surname><given-names>O</given-names></name><name><surname>Yinnon</surname><given-names>AM</given-names></name><article-title>Analysis and impact of infectious disease consultations in a general hospital</article-title><source>J Hosp Infect</source><year>1998</year><volume>40</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0195-6701(98)90023-8</pub-id><pub-id pub-id-type="pmid">9777520</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Pavese</surname><given-names>P</given-names></name><name><surname>Sellier</surname><given-names>E</given-names></name><name><surname>Laborde</surname><given-names>L</given-names></name><name><surname>Gennai</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>JP</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>P</given-names></name><article-title>Requesting physicians' experiences regarding infectious disease consultations</article-title><source>BMC Infect Dis</source><year>2011</year><volume>11</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-11-62</pub-id><pub-id pub-id-type="pmid">21401916</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Sellier</surname><given-names>E</given-names></name><name><surname>Pavese</surname><given-names>P</given-names></name><name><surname>Gennai</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>JP</given-names></name><name><surname>Labar&#x000e8;re</surname><given-names>J</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>P</given-names></name><article-title>Factors and outcomes associated with physicians' adherence to recommendations of infectious disease consultations for inpatients</article-title><source>J Antimicrob Chemother</source><year>2010</year><volume>65</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1093/jac/dkp406</pub-id><pub-id pub-id-type="pmid">19910328</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Nagao</surname><given-names>M</given-names></name><name><surname>Iinuma</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Shirano</surname><given-names>M</given-names></name><name><surname>Matsushima</surname><given-names>A</given-names></name><name><surname>Takakura</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Ichiyama</surname><given-names>S</given-names></name><article-title>Close cooperation between infectious disease physicians and attending physicians can result in better management and outcome for patients with Staphylococcus aureus bacteraemia</article-title><source>Clin Microbiol Infect</source><year>2010</year><volume>16</volume><fpage>1783</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2010.03156.x</pub-id><pub-id pub-id-type="pmid">21077985</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Lo</surname><given-names>E</given-names></name><name><surname>Rezai</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>AT</given-names></name><name><surname>Madariaga</surname><given-names>MG</given-names></name><name><surname>Phillips</surname><given-names>M</given-names></name><name><surname>Brobbey</surname><given-names>W</given-names></name><name><surname>Schwartz</surname><given-names>DN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Weinstein</surname><given-names>RA</given-names></name><name><surname>Trenholme</surname><given-names>GM</given-names></name><article-title>Why don't they listen? Adherence to recommendations of infectious disease consultations</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>1212</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1086/383315</pub-id><pub-id pub-id-type="pmid">15127330</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Solomkin</surname><given-names>JS</given-names></name><name><surname>Mazuski</surname><given-names>JE</given-names></name><name><surname>Baron</surname><given-names>EJ</given-names></name><name><surname>Sawyer</surname><given-names>RG</given-names></name><name><surname>Nathens</surname><given-names>AB</given-names></name><name><surname>DiPiro</surname><given-names>JT</given-names></name><name><surname>Buchman</surname><given-names>T</given-names></name><name><surname>Dellinger</surname><given-names>EP</given-names></name><name><surname>Jernigan</surname><given-names>J</given-names></name><name><surname>Gorbach</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>AW</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><article-title>Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1086/378702</pub-id><pub-id pub-id-type="pmid">14523762</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Stevens</surname><given-names>DL</given-names></name><name><surname>Bisno</surname><given-names>AL</given-names></name><name><surname>Chambers</surname><given-names>HF</given-names></name><name><surname>Everett</surname><given-names>ED</given-names></name><name><surname>Dellinger</surname><given-names>P</given-names></name><name><surname>Goldstein</surname><given-names>EJ</given-names></name><name><surname>Gorbach</surname><given-names>SL</given-names></name><name><surname>Hirschmann</surname><given-names>JV</given-names></name><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>Montoya</surname><given-names>JG</given-names></name><name><surname>Wade</surname><given-names>JC</given-names></name><article-title>Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><fpage>1373</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1086/497143</pub-id><pub-id pub-id-type="pmid">16231249</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Campbell</surname><given-names>GD</given-names></name><name><surname>Dean</surname><given-names>NC</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name><name><surname>Musher</surname><given-names>DM</given-names></name><name><surname>Niederman</surname><given-names>MS</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Whitney</surname><given-names>CG</given-names></name><article-title>Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>2</issue><fpage>S27</fpage><lpage>S72</lpage><pub-id pub-id-type="doi">10.1086/511159</pub-id><pub-id pub-id-type="pmid">17278083</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Tellado</surname><given-names>JM</given-names></name><name><surname>Sitges-Serra</surname><given-names>A</given-names></name><name><surname>Barcenilla</surname><given-names>F</given-names></name><name><surname>Palomar</surname><given-names>M</given-names></name><name><surname>Serrano</surname><given-names>R</given-names></name><name><surname>Barber&#x000e1;n</surname><given-names>J</given-names></name><name><surname>Moya</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Rodr&#x000ed;guez</surname><given-names>JA</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Prieto</surname><given-names>J</given-names></name><article-title>Guidelines for the empirical antibiotic treatment of intraabdominal infections [Article in Spanish]</article-title><source>Rev Esp Quimioter</source><year>2005</year><volume>18</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">16130041</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Cisneros-Herreros</surname><given-names>JM</given-names></name><name><surname>Cobo-Reinoso</surname><given-names>J</given-names></name><name><surname>Pujol-Rojo</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez-Ba&#x000f1;o</surname><given-names>J</given-names></name><name><surname>Salavert-Llet&#x000ed;</surname><given-names>M</given-names></name><article-title>Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Espa&#x000f1;ola de Enfermedades Infecciosas y Microbiolog&#x000ed;a Cl&#x000ed;nica [Article in Spanish]</article-title><source>Enferm Infecc Microbiol Clin</source><year>2007</year><volume>25</volume><fpage>111</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S0213-005X(07)74242-8</pub-id><pub-id pub-id-type="pmid">17288909</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Alvarez</surname><given-names>F</given-names></name><name><surname>Bouza</surname><given-names>E</given-names></name><name><surname>Garc&#x000ed;a-Rodr&#x000ed;guez</surname><given-names>JA</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name><name><surname>Picazo</surname><given-names>JJ</given-names></name><name><surname>Sobradillo</surname><given-names>V</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Moya Mir</surname><given-names>M</given-names></name><name><surname>P&#x000e9;rez Escanilla</surname><given-names>F</given-names></name><name><surname>Puente</surname><given-names>T</given-names></name><name><surname>Ca&#x000f1;ada</surname><given-names>JL</given-names></name><name><surname>Mart&#x000ed;nez Ortiz De Z&#x000e1;rate</surname><given-names>M</given-names></name><article-title>Second consensus statement on the use of antimicrobial drugs in chronic obstructive pulmonary disease exacerbations [Article in Spanish]</article-title><source>Rev Esp Quimioter</source><year>2002</year><volume>15</volume><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">12607552</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Charlson</surname><given-names>ME</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>KL</given-names></name><name><surname>MacKenzie</surname><given-names>CR</given-names></name><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J Chronic Dis</source><year>1987</year><volume>40</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/0021-9681(87)90171-8</pub-id><pub-id pub-id-type="pmid">3558716</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Mc Cabe</surname><given-names>WR</given-names></name><name><surname>Jackson</surname><given-names>GG</given-names></name><article-title>Gram-negative bacteremia. II. Clinical, laboratory and therapeutic observations</article-title><source>Arch Intern Med</source><year>1962</year><volume>110</volume><fpage>856</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1001/archinte.1962.03620240038007</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Erbay</surname><given-names>A</given-names></name><name><surname>Bodur</surname><given-names>H</given-names></name><name><surname>Ak&#x00131;nc&#x00131;</surname><given-names>E</given-names></name><name><surname>&#x000c7;olpan</surname><given-names>A</given-names></name><article-title>Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey</article-title><source>J Hosp Infect</source><year>2005</year><volume>59</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2004.07.026</pub-id><pub-id pub-id-type="pmid">15571854</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Kunin</surname><given-names>CM</given-names></name><name><surname>Tupasi</surname><given-names>T</given-names></name><name><surname>Craig</surname><given-names>WA</given-names></name><article-title>Use of antibiotics. A brief exposition of the problem and some tentative solutions</article-title><source>Ann Intern Med</source><year>1973</year><volume>79</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">4795880</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Petrak</surname><given-names>RM</given-names></name><name><surname>Sexton</surname><given-names>DJ</given-names></name><name><surname>Butera</surname><given-names>ML</given-names></name><name><surname>Tenenbaum</surname><given-names>MJ</given-names></name><name><surname>MacGregor</surname><given-names>MC</given-names></name><name><surname>Schmidt</surname><given-names>ME</given-names></name><name><surname>Joseph</surname><given-names>WP</given-names></name><name><surname>Kemmerly</surname><given-names>SA</given-names></name><name><surname>Dougherty</surname><given-names>MJ</given-names></name><name><surname>Bakken</surname><given-names>JS</given-names></name><name><surname>Curfman</surname><given-names>MF</given-names></name><name><surname>Martinelli</surname><given-names>LP</given-names></name><name><surname>Gainer</surname><given-names>RB</given-names></name><article-title>The value of an infectious diseases specialist</article-title><source>Clin Infect Dis</source><year>2003</year><volume>36</volume><fpage>1013</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1086/374245</pub-id><pub-id pub-id-type="pmid">12684914</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Fraser</surname><given-names>GL</given-names></name><name><surname>Stogsdill</surname><given-names>P</given-names></name><name><surname>Dickens</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Wennberg</surname><given-names>DE</given-names></name><name><surname>Smith</surname><given-names>RP</given-names><suffix>Jr</suffix></name><name><surname>Prato</surname><given-names>BS</given-names></name><article-title>Antibiotic optimization. An evaluation of patient safety and economic outcomes</article-title><source>Arch Intern Med</source><year>1997</year><volume>157</volume><fpage>1689</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1001/archinte.1997.00440360105012</pub-id><pub-id pub-id-type="pmid">9250230</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Sellier</surname><given-names>E</given-names></name><name><surname>Labar&#x000e8;re</surname><given-names>J</given-names></name><name><surname>Gennai</surname><given-names>S</given-names></name><name><surname>Bal</surname><given-names>G</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>P</given-names></name><name><surname>Pavese</surname><given-names>P</given-names></name><article-title>Compliance with recommendations and clinical outcomes for formal and informal infectious disease specialist consultations</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2011</year><volume>30</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1007/s10096-011-1172-7</pub-id><pub-id pub-id-type="pmid">21311942</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Lemmen</surname><given-names>SW</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Frank</surname><given-names>U</given-names></name><name><surname>Daschner</surname><given-names>FD</given-names></name><article-title>Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital</article-title><source>Scand J Infect Dis</source><year>2001</year><volume>33</volume><fpage>219</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1080/00365540151060923</pub-id><pub-id pub-id-type="pmid">11303814</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Gums</surname><given-names>JG</given-names></name><name><surname>Yancey</surname><given-names>RW</given-names><suffix>Jr</suffix></name><name><surname>Hamilton</surname><given-names>CA</given-names></name><name><surname>Kubilis</surname><given-names>PS</given-names></name><article-title>A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team</article-title><source>Pharmacotherapy</source><year>1999</year><volume>19</volume><fpage>1369</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1592/phco.19.18.1369.30898</pub-id><pub-id pub-id-type="pmid">10600085</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Nathwani</surname><given-names>D</given-names></name><article-title>Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>51</volume><issue>2</issue><fpage>ii37</fpage><lpage>ii44</lpage><pub-id pub-id-type="pmid">12730141</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Tenenbaum</surname><given-names>MJ</given-names></name><article-title>Infectious diseases consultative recommendations: If heard, they can be listened to</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>1219</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1086/383327</pub-id><pub-id pub-id-type="pmid">15127331</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>M&#x000e9;an</surname><given-names>M</given-names></name><name><surname>Pavese</surname><given-names>P</given-names></name><name><surname>Tudela</surname><given-names>E</given-names></name><name><surname>Dinh-Van</surname><given-names>KA</given-names></name><name><surname>Mallaret</surname><given-names>MR</given-names></name><name><surname>Stahl</surname><given-names>JP</given-names></name><article-title>Consultations with infectious disease specialists for patients in a teaching hospital: Adherence in 174 cases [Article in French]</article-title><source>Presse Med</source><year>2006</year><volume>35</volume><fpage>1461</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1016/S0755-4982(06)74835-7</pub-id><pub-id pub-id-type="pmid">17028534</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>McQuillen</surname><given-names>DP</given-names></name><name><surname>Petrak</surname><given-names>RM</given-names></name><name><surname>Wasserman</surname><given-names>RB</given-names></name><name><surname>Nahass</surname><given-names>RG</given-names></name><name><surname>Scull</surname><given-names>JA</given-names></name><name><surname>Martinelli</surname><given-names>LP</given-names></name><article-title>The value of infectious diseases specialists: non-patient care activities</article-title><source>Clin Infect Dis</source><year>2008</year><volume>47</volume><fpage>1051</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1086/592067</pub-id><pub-id pub-id-type="pmid">18781883</pub-id></mixed-citation></ref></ref-list></back></article>